Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Cel-Sci Corporation (AMEX:CVM)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider
Location
8229 Boone Boulevard, Suite 802
Vienna, VA 22182
Phone: (703) 506-9460
Fax: (703) 506-9471
Employees (last reported count): 32
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 11%
·Over the last 6 months:
 · one insider sell; 43.0K shares
  (1.6% of insider shares)
·Institutional: 2% (2% of float)
(10 institutions)
·Net Inst. Buying: 53.0K shares (+12.18%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Cel-Sci Corporation is involved in the research and development of several drugs and vaccines. The Company's first and main product, MULTIKINE, is being developed for the treatment of head and neck cancer. The Company is also conducting studies with MULTIKINE in prostate cancer patients and is planning to start a cervical cancer study by the first quarter of 2001. The Company's heteroconjugate technology, L.E.A.P.S. (Ligand Epitope Antigen Presentation System), has potential applications in the development of treatments and/or vaccines against various diseases. The Company also has completed Phase II human clinical trials of a preventive vaccine against HIV infection.
More from Market Guide: Expanded Business Description

Financial Summary
CVM is involved in the research and development of certain drugs and vaccines using the Company's proprietary cell culture technologies. CVM's first product, MULTIKINE, is being tested to determine if it is effective in improving the immune response of cancer patients. For the nine months ended 6/01, revenues increased 84% to $551 thousand. Net loss rose 22% to $8.2 million. Revenues reflect interest accrued on investments. Higher loss reflects clinical trial expenses.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Geert Kersten, 41
CEO, Sec., Treasurer, Director
$333K$137K
Maximilian De Clara, 70
Pres, Director
969K1.4M
Michael Luecke, 58
Sr. VP of Bus. Devel.
159K44K
Patricia Prichep, 49
Sr. VP of Operations
124K90K
Eyal Talor, Ph.D., 44
Sr. VP of Research and Manufacturing
162K275K
Dollar amounts are as of 30-Sep-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- AMEX:CVMAs of 31-Aug-2001
Price and Volume
52-Week Low
on 21-Dec-2000
$1.00 
Recent Price$1.33 
52-Week High
on 7-Sep-2000
$3.438
Beta1.01 
Daily Volume (3-month avg)50.3K
Daily Volume (10-day avg)34.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-58.3%
52-Week Change
relative to S&P500
-44.0%
Share-Related Items
Market Capitalization$32.3M
Shares Outstanding24.3M
Float21.6M
Dividends & Splits
Annual Dividendnone 
Last Split: 1 for 10 on 1-May-1995
Per-Share Data
Book Value (mrq)$0.20 
Earnings (ttm)-$0.47 
Earnings (mrq)-$0.09 
Sales (ttm)$0.03 
Cash (mrq)$0.13 
Valuation Ratios
Price/Book (mrq)6.67 
Price/EarningsN/A 
Price/Sales (ttm)40.47 
Income Statements
Sales (ttm)$694.0K
EBITDA (ttm)-$9.77M
Income available to common (ttm)-$9.97M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsSep 30
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-94.28%
Return on Equity (ttm)-99.93%
Financial Strength
Current Ratio (mrq)9.81 
Debt/Equity (mrq)0 
Total Cash (mrq)$3.17M
Short Interest
As of 8-Aug-2001
Shares Short8,000 
Percent of Float0.0%
Shares Short
(Prior Month)
8,000 
Short Ratio0.13 
Daily Volume61.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.